- Home
- ARQT vs DAN Comparison
ARQT vs DAN Comparison
Compare ARQT & DAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- DAN
- Stock Information
- Founded
- ARQT 2016
- DAN 1904
- Country
- ARQT United States
- DAN United States
- Employees
- ARQT N/A
- DAN N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- DAN Auto Parts:O.E.M.
- Sector
- ARQT Health Care
- DAN Consumer Discretionary
- Exchange
- ARQT Nasdaq
- DAN Nasdaq
- Market Cap
- ARQT 2.1B
- DAN 2.4B
- IPO Year
- ARQT 2020
- DAN N/A
- Fundamental
- Price
- ARQT $24.38
- DAN $21.49
- Analyst Decision
- ARQT Strong Buy
- DAN Buy
- Analyst Count
- ARQT 7
- DAN 5
- Target Price
- ARQT $22.17
- DAN $26.00
- AVG Volume (30 Days)
- ARQT 2.5M
- DAN 2.3M
- Earning Date
- ARQT 10-28-2025
- DAN 10-29-2025
- Dividend Yield
- ARQT N/A
- DAN 1.86%
- EPS Growth
- ARQT N/A
- DAN N/A
- EPS
- ARQT N/A
- DAN 0.39
- Revenue
- ARQT $317,929,000.00
- DAN $9,957,000,000.00
- Revenue This Year
- ARQT $85.27
- DAN N/A
- Revenue Next Year
- ARQT $30.70
- DAN N/A
- P/E Ratio
- ARQT N/A
- DAN $55.23
- Revenue Growth
- ARQT 129.21
- DAN 17.78
- 52 Week Low
- ARQT $8.45
- DAN $7.58
- 52 Week High
- ARQT $27.08
- DAN $22.13
- Technical
- Relative Strength Index (RSI)
- ARQT 64.85
- DAN 64.57
- Support Level
- ARQT $19.60
- DAN $20.00
- Resistance Level
- ARQT $27.08
- DAN $22.13
- Average True Range (ATR)
- ARQT 1.25
- DAN 0.71
- MACD
- ARQT 0.21
- DAN 0.16
- Stochastic Oscillator
- ARQT 63.91
- DAN 81.71
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About DAN Dana Incorporated
Dana Inc is engaged in the designing and manufacturing of efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company has four operating segments: Light Vehicles, Power Technologies, Commercial Vehicle, and Off-Highway. The Light Vehicles segment generates the majority portion of revenue by providing products to support light vehicle OEMs. Its products are designed for light trucks, SUVs, CUVs, vans, and passenger cars.